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Kynurenic acid (KYNA), a neuroactive metabolite of tryptophan degradation, acts as
an endogenous N-methyl-D-aspartate receptor (NMDAR) antagonist. Elevated levels
of KYNA have been observed in pregnant women after viral infections and are
considered to play a role in neurodevelopmental disorders. However, the consequences
of KYNA-induced NMDAR blockade in human cortical development still remain elusive.
To study the potential impact of KYNA on human neurodevelopment, we used an in vitro
system of multipotent cortical progenitors, i.e., radial glia cells (RGCs), enriched from
human cerebral cortex at mid-gestation (16–19 gestational weeks). KYNA treatment
significantly decreased RGCs proliferation and survival by antagonizing NMDAR. This
alteration resulted in a reduced number of cortical progenitors and neurons while number
and activation of astrocytes increased. KYNA treatment reduced differentiation of RGCs
into GABAergic neurons, while differentiation into glutamatergic neurons was relatively
spared. Furthermore, in mixed cortical cultures KYNA triggered an inflammatory response
as evidenced by increased levels of the pro-inflammatory cytokine IL-6. In conclusion,
elevated levels of KYNA play a significant role in human RGC fate determination by
antagonizing NMDARs and by activating an inflammatory response. The altered cell
composition observed in cell culture following exposure to elevated KYNA levels suggests
a mechanism for impairment of cortical circuitry formation in the fetal brain after viral
infection, as seen in neurodevelopmental disorders such as schizophrenia.
Keywords: human fetal brain, cerebral cortex, tissue culture, KYNA, NMDARs, neurogenesis, cortical progenitor
cells
INTRODUCTION
Kynurenic acid (KYNA) is an intermediate metabolite of the kynurenine pathway and the only
naturally occurring antagonist of the glutamatergic NMDA receptor (NMDAR) in the human brain
(Stone, 2013). In the brain, KYNA is synthesized in astrocytes by the irreversible transamination
of L-kynurenine, the first major catabolic product of tryptophan. Elevated levels of KYNA
have been found in the cerebrospinal fluid and in post-mortem brains of adult schizophrenia
(Sch) patients (Erhardt et al., 2001; Schwarcz et al., 2001; Sathyasaikumar et al., 2011; Holtze
et al., 2012). Both stress and infections, in rats activates indoleamine 2,3 dioxygenase (IDO),
a cytokine responsive enzyme that catalyzes the formation of kynurenine, which may impair
brain development (Pocivavsek et al., 2014; Notarangelo and Pocivavsek, 2016). Furthermore,
environmental insults during development, such as maternal influenza infection, increase the risk
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for Sch and related disorders (Wright et al., 1995; Stöber et al.,
2002; Limosin et al., 2003; Brown, 2012). In rodents, KYNA can
cross the placental and fetal blood-brain barriers (Heyes et al.,
1990; Scharfman and Goodman, 1998) and induce secretion of
various pro-inflammatory cytokines, such as interferon gamma
(IFN-γ) and interleukin 6 (IL-6), from fetal astrocytes (Meyer
et al., 2011). Additionally, in vitro studies have demonstrated that
IFN-γ and IL-6 can activate human fetal astrocytes to synthesize
increased levels of KYNA (Guillemin et al., 2001). Thus, exposure
of the fetal brain to KYNA may establish a positive feed-back
loop, whereby KYNA levels are further enhanced (Guillemin
et al., 2001; Meyer et al., 2011; Schwieler et al., 2015).
Glutamate acting via NMDARs has a trophic effect during
development, and may play an important role in determining
the selective survival of neurons and their proper connections
(LoTurco et al., 1991; Haydar et al., 2000; Balasz, 2006). This is
particularly pertinent to a possible role for disturbed NMDAR
function in Sch, as an alteration or reduction of NMDARs has
been demonstrated in medication-free Sch patients (Akbarian
et al., 1996; Pilowsky et al., 2006), and abnormal glutamatergic
activity has been reported in the pathophysiology of Sch (Deutsch
et al., 1989; Coyle, 1996; Belforte et al., 2010). Furthermore,
NMDARs are abundantly expressed in the developing human
cerebral cortex at midgestation (Bagasrawala et al., 2016) Many
animal models of Sch mimic a transient NMDAR hypofunction
during development using NMDAR antagonists such as MK-801
(Ikonomidou et al., 1999), phencyclidine (PCP;Wang et al., 2001;
Radonjic´ et al., 2008) and ketamine (Breier et al., 1997; Rujescu
et al., 2006).
Even though it is known that there is a higher incidence of
Sch in people exposed to viral infections in utero (Bale et al.,
2010; Brown and Derkits, 2010; Selemon and Zecevic, 2015),
presumably due to an inflammatory response and increased levels
of KYNA, it is still unclear how elevated levels of KYNA affect the
developing human brain. The goal of this study was to elucidate
the role of KYNA as an endogenous NMDAR antagonist in
the human fetal brain. As experimental manipulation of the
developing human brain in vivo is not possible, we established
an in vitro system to test the effects of KYNA on human cortical
progenitor cells.
Radial glia cells (RGCs) are multipotent cortical progenitor
cells capable of generating all neural cell types, including
subpopulations of intermediate and interneuron progenitors,
neurons, astrocytes and oligodendrocytes (Howard et al., 2006;
Mo et al., 2007; Mo and Zecevic, 2009; Hansen et al., 2010, 2013;
Lui et al., 2011; Yu and Zecevic, 2011; Ma et al., 2013; Radonjic´
et al., 2014). Specifically, we were interested in how exposure
to KYNA affects survival, proliferation, and specification of
RGCs into various cell types, including cortical interneurons
and pyramidal cells. We demonstrated that elevated levels of
KYNA, through a NMDAR blockade, not only reduced survival
and proliferation of RGCs, but significantly altered the progeny
of cortical RGCs. Treatment with KYNA promoted gliogenesis
at the expense of neurogenesis, and increased activation of
astrocytes. Moreover, we detected increased levels of a pro-
inflammatory cytokine, IL-6, which suggests an initiation of
an inflammatory response. The combined effects of a NMDAR
blockade and an inflammatory response could impair cortical
circuitry formation in utero and in so doing contribute to
the pathophysiology of neurodevelopmental illness, possibly
including the adult-onset disorder of schizophrenia.
MATERIALS AND METHODS
Human Fetal Brain Tissue
Human fetal brain tissue (n = 8), free of any developmental
abnormalities, at 16–19 gw was obtained with written informed
consent and the approval of University of Connecticut Health
Ethics Committee, from the Human Developmental Biology
Resource (Newcastle University, Newcastle upon Tyne, England)
and the Tissue Repository of The Albert Einstein College of
Medicine (Bronx, NY, USA), (Table 1). Transport of the human
material was done on ice, following all necessary requirements
and regulations set by the Institutional Ethics Committees, of our
institution and respective tissue repositories.
The age of the tissue was determined by the following criteria:
crown-rump length, weeks after ovulation, and anatomical
landmarks. The tissue was transported on ice in Hank’s Balanced
Salt Solution (HBSS; Life Technologies, Grand Island, NY, USA)
from the aforementioned brain repositories to the lab. A small
unfixed piece (1 cm2) of the dorsal telencephalic region was used
to generate dissociated cell cultures (Zecevic et al., 2005; Radonjic´
et al., 2014). We always tried to used multiple methods on the
same case, but not all the cases were available for every method
used in this study, as specified in Table 1.
Dissociated Mixed Cell Culture and
Enrichment of RGCs
A previously published protocol (Mo and Zecevic, 2009) was
used to establish dissociated mixed cell cultures. As briefly
described here, the isolated tissue was dissociated mechanically
and enzymatically at 37◦C for 30minwith 0.025% trypsin (Gibco,
Beverly, MA, USA), followed by addition of DNase (Sigma-
Aldrich, St Louis, MO, USA; 2mg/mL), washing with HBSS
(Life Technologies) and suspension in proliferation medium
(PM; Figure 1A). The PM consisted of DMEM/F12 (Life
Technologies) supplemented with 10 ng/mL of basic fibroblast
growth factor (bFGF, Peprotech, Rocky Hill, NJ, USA), 10 ng/mL
of epidermal growth factor (EGF, Millipore, Billerica, MA, USA),
TABLE 1 | Description of human fetal tissue and methods used.
Case Sex Gestational Method used
number week
1 MALE 16 qPCR, Western blot, Immunocytochemistry, ELISA
2 MALE 17 qPCR, Western blot, Immunocytochemistry, ELISA
3 MALE 18 qPCR, Western blot, Immunocytochemistry, ELISA
4 MALE 19 qPCR, Western blot, Immunocytochemistry, ELISA
5 MALE 16 Immunocytochemistry (Mixed cells), ELISA
6 MALE 18 Immunocytochemistry (Mixed cells), ELISA
7 MALE 18 Immunocytochemistry (Mixed cells), ELISA
8 MALE 19 Immunocytochemistry (Mixed cells), ELISA
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FIGURE 1 | Enriched RGCs from human fetal cortex using MACS. (A) Dissociated mixed cell cultures are established from the telencephalic wall (red box), and
RGCs are enriched from these cultures through magnetic sorting (MACS) using anti-CD15 micro-beads. (B) Enriched RGCs are co-labeled for CD15 and radial glia
markers BLBP or GFAP after 3 DIV of proliferation. Nuclear stain: bisbensimide (BB).
and B27 (Life Technologies). Seven to ten days after plating, the
cells proliferated in PM and reached 80% confluency whereupon
they were used for experiments on activated astrocytes including
sandwich ELISA, and to generate RGC cultures.
RGCs were isolated from mixed cell cultures using the cell
surface glycan marker CD15 via magnetic columns (MACS,
Miltenyi Biotec, Auburn, CA, USA) (Mo et al., 2007; Radonjic´
et al., 2014). Enriched RGCs were fixed after 2 hrs and co-labeled
for surface antigen CD15 and either brain lipid binding protein
(BLBP; 97.8%) or glial fibrillary acidic protein (GFAP; 99.1%),
both markers of RGCs (Figure 1B), demonstrating the purity
of enriched RGC cultures. The expression of the NR1 gene and
protein in cell lysates as well as NR1 expression on different cell
types using double immunostaining, was done after 3 days in
vitro (DIV) in PM, and after 7 DIV in differentiation medium
(DM), which is devoid of growth factors. RGCs plated on poly-
D-lysine (Sigma-Aldrich) coated coverslips (12mm) at a density
of 250,000 cells/ml were used for immunocytochemistry. Poly-
D-lysine coated six wells (10 cm2 growth area/well) plated with 2
million cells/ml were used to collect cell lysates for total protein
and RNA isolation.
Pharmacological Treatments of Cell
Cultures
RGCs cultures were treated with each of these substances: KYNA,
NMDAR-specific antagonist D-amino phosphonovalerate
(D-APV), and nicotinic acetylcholine receptor (nAChR)
antagonist Tubocurarine chloride (TBC), to determine if the
effect of KYNA was mediated through NMDARs or nAChRs.
Concentration-response curves were first plotted 48 h after
RGC cultures underwent treatments with eight different
concentrations (0.001–100.0 µM) of KYNA (Sigma Aldrich),
D-APV (Tocris Biosciences, Bristol, UK) and TBC. KYNA was
dissolved in DMSO (Dimethyl sulphoxide, Sigma Aldrich),
and therefore two sets of controls were maintained: (1) RGCs
grown only in PM, (2) RGCs grown in PM containing DMSO.
In all analyzed experiments there was no difference between
control PM and PM+DMSO, hence PM+DMSO results were
represented in graphs as the control. The effective concentration
at which 50% of the cell population was affected (EC50) was
determined in both assays to decide the treatment concentrations
to be used for further experiments, where cells were analyzed
after 3 DIV in PM, and after 7 DIV in DM.
Cell Survival Assay
A live/dead assay (Molecular Probes, Eugene, OR, USA) was
performed after 48 h of KYNA treatment to assess its effect
on cell viability. The kit enables detection of live cells via the
cell-permeant molecule calcein acetoxymethyl that gives a green
fluorescence in the presence of intracellular esterases. Dead cells
which have lost the intact cell membrane appear red due to
incorporation of an ethidium homodimer into their degrading
nucleic acids.
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Proliferation Assay
At the end of the 48 h KYNA treatment period, cells were
fixed and immunostained with anti-Ki67 antibody. Ki67 is a
marker of cells undergoing mitotic divisions or proliferation. The
percentage of Ki67+ cells was determined from the total number
of cells marked with the nuclear stain bisbenzimide (BB).
Immunocytochemistry (ICC)
Cells growing in vitro on coverslips were fixed with 4%
paraformaldehyde, washed with PBS (phosphate buffer saline),
blocked (0.2% bovine serum albumin (BSA), 0.01% Triton X-
100, PBS) for 1 h at room temperature (RT), and incubated with
primary antibodies (see Table 2) at 4◦C overnight. The specificity
of each primary antibody has been previously tested and shown
in the data sheets obtained from the respective manufacturers.
Specificity of staining was validated by replacing the primary
antibody with the normal serum from the animal in which
the antibody was produced, which resulted in the absence of
fluorescent signal. The following day, fluorophore-conjugated
secondary antibodies goat anti-mouse Alexa-488 (Jackson
ImmunoResearch, Lot no. 104763), and goat anti-rabbit Alexa-
555 (Molecular Probes, Catalog no. A21428) at a concentration of
1µg/ml each were applied for 2 h at RT, followed by the nuclear
stain BB for 1 min. All immunostained coverslips were mounted
using the anti-fade reagent Fluoromount-G (Southern Biotech,
Birmingham, AL, USA) to preserve the fluorescence.
Image Analysis and Statistical Tests
Immunolabeled samples were visualized using an Axioscope
microscope (Zeiss, Germany) equipped with Axiovision software
and photographed using a digital camera with 63X lens. During
acquisition of images of double immunolabeled sections the
focus, brightness and contrast were constant. Twelve random
images were taken from each coverslip and analyzed in Adobe
Photoshop (v. 7.0), with consistent quality adjustments for
contrast, brightness and color balance and used for cell counting.
We quantified cells labeled with each marker in its respective
channel in Photoshop, as well as cells that show immunoreaction
for both applied antibodies. The total cell number in the optical
field was determined by quantifying cell nuclei labeled with a
nuclear dye bisbensamide (BB). The percentage of double labeled
cells was then calculated from a total cell count and averaged
across the four coverslips/12 pictures/4 brains for each marker
and each treatment and plotted in the bar graphs.
Western Blot (WB)
Cells were homogenized in lysis buffer (50mM Tris–HCl pH
7.4, 150mM NaCl, 1% NP-40, 1 mM phenylmethylsulfonyl
fluoride, Sigma Aldrich, and protease inhibitor cocktail, Thermo
Scientific, Agawam, MA, USA) on ice for 30 min, centrifuged
at 14,000 × g for 15 min at 4◦C, and the supernatants were
collected as the cell lysates. The protein content of the samples
was analyzed using the BCA protein estimation colorimetric
assay (Thermo Scientific). Twenty micrograms of protein was
loaded in each well and proteins were separated on 4–15%
gradient polyacrylamide gels (Bio-Rad, Portland. ME, USA) at
110 v for 75 min. Samples were run, on three separate gels,
to obtain results in triplicates. The separated proteins were
transferred onto polyvinylidene fluoride (PVDF) membranes
at 100 v for 60 min. A Ponceau stain on every blot, and a
Coomassie stain for every gel was performed to confirm complete
transfer of separated proteins. After blocking with 5% milk
in TBS-T (1.0% Tween-20, PBS, 0.1% Triton X-100, distilled
water; pH 7.4), the membrane (blot) was incubated with primary
antibodies diluted in blocking solution (0.1 M Tris, 2% non-
fat dry milk, 0.15 M NaCl, 0.01% Na-azide, pH 7.4) against the
proteins of interest at 4◦C (Table 2) overnight. The blot was
washed three times, with 1X TBS-T (10% Tween, PBS, 0.1%
TritonX-100, distilled water), and incubated with horseradish
peroxidase (HRP)-conjugated secondary antibodies (Millipore)
for 2 h at RT., Blots were incubated with SuperSignal West Dura
Extended Duration Substrate (Thermo Scientific), and imaged on
ChemiDoc MP (Bio-Rad) digital imaging system. The loading
control for each blot was GAPDH (primary antibody dilution
1:5000). Each membrane was used only once, no stripping
or re-probing has been performed. The density of each band
was determined in Adobe Photoshop (v.7.0) using histogram
analysis. The values obtained for each band were divided by
the value of the corresponding GAPDH band. The averaged
values obtained from KYNA treated groups were normalized to
TABLE 2 | List of primary antibodies used.
Primary antibody Cell type identified Species Concentration Catalog number Company
CD15 Radial Glia (RGC) Mouse 2 µg/ml #MS-1259-P Thermo Scientific
BLBP RGC Rabbit 1.25 µg/ml ab27171 Abcam
GFAP RGC, Astrocyte Mouse, rabbit 5 µg/ml Z 0334 Dako
Tbr2 Intermediate Progenitor Rabbit 2 µg/ml ab23345 Abcam
Nkx2.1 Interneuron Progenitor Rabbit 10 µg/ml ab76013 Abcam
βIII tubulin Neuron Mouse, rabbit 2 µg/ml 065M4820V Sigma-Aldrich
Tbr1 Glutamatergic Neuron Rabbit 5 µg/ml 20932-1-AP Proteintech
GABA Interneuron Rabbit 5 µg/ml A2052 Sigma-Aldrich
CalR Interneuron Rabbit 1 µg/ml 7699/4 Swant
Ki67 Proliferating Cells Rabbit 1 µg/ml ab15580 Abcam
GAPDH Housekeeping Mouse 0.2 µg/ml MAB374 Millipore
NR1 – Mouse 10 µg/ml 75-272 NeuroMab
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TABLE 3 | List of primers used for qPCR.
Genes Cell type identified Forward primer sequence Reverse primer sequence
Nestin RGC 5′′-GCC CTG ACC ACT CCA GTT TA-3′′ 5′′GGA GTC CTG GAT TTC CTT CC-3′′
Tbr2 Intermediate progenitor 5′′-GGG CAC CTA TCA GTA CAG CCA-3′′ 5′′-AAG GAA ACA TGC GCC TGC-3′′
Nkx2.1 Interneuron progenitor 5′′-CAC GCA GGT CAA GAT CTG GTT-3′′ 5′′-TTG CCG TCT TTC ACC AGG A-3′′
Neurogenin Neuron 5′′-GCATCAAGA AGACACGCAGACTGA-3′′ 5′′-TCTCGATCTTGGTTAGCTTGGCGT-3′′
Tbr1 Glutamatergic neuron 5′′-TCT GAG CTT CGT CAC AGT TTC-3′′ 5′′-GCT GTT GTA GGC TCC GTT G-3′′
Gad65/67 Interneuron 5′′-CCT CAA CTA TGT CCG CAA GAC-3′′ 5′′-TGT GCG AAC CCC ATA CTT CAA-3′′
Gfap Astrocyte 5′′-CTG CGG CTC GAT CTG GTT-3′′ 5′′-TCC AGC GAC TCA ATC TTC CTC-3′′
Grin1 – 5′′-CCA GTC AAG AAG GTG ATC TGC AC-3′′ 5′′-TTC ATG GTC CGT GCC AGC TTG A-3′′
the control (DMSO) group to overcome individual differences
between samples.
Real-Time Polymerase Chain Reaction
Cells were treated with ice-cold TRIZOL R© reagent (Invitrogen,
Carlsbad, CA, USA; 1ml/10 cm2 of surface area) and were
broken down mechanically and through alternate freeze-thaw
cycles. Chloroform (200 µl/1ml of Trizol) was added to the
homogenates, and tubes were vortexed, incubated (15 min
at 4◦C), and centrifuged (13,000 × g for 15 min at 4◦C).
The upper transparent phase was collected in sterile tubes,
incubated with isopropanol (500 µl/tube; 20 min at RT), and
centrifuged (13,000 × g for 15 min at 4◦C). The pellets were
incubated with 75% ethanol (4◦C) and centrifuged (13,000 ×
g for 15 min). The pellets containing RNA were air dried
and dissolved in 5% RNase Out solution. RNA concentrations
were determined using the NanoDrop technology. cDNA was
synthesized by reverse transcriptase-PCR using the First Strand
Synthesis SuperScript III kit (Invitrogen). The SYBR Green
(Applied Biosystems, Cheshire, UK) protocol was used to analyze
the expression levels of mRNA from the cDNA samples (see
Table 3 for list of genes and primers) by performing real
time PCR using the CFX96 Connect R© thermocycler (Bio-
Rad). The real time PCR protocol involves a heating step
to 95◦C for 2 min followed by 40 cycles at 95◦C for 15 s,
at 55◦C for 15 s, and at 68◦C for 20 s. Cycle of threshold
(Ct) values were used to calculate the 11Ct values, and the
formula 2−11Ct was used to determine the mRNA expression
level relative to the control sample which has an arbitrary
value of 1.
Sandwich Enzyme Linked Immunosorbent
Assay (Sandwich ELISA)
The eBioscience High Sensitivity human anti-IL6 ELISA (San
Diego, CA) kit was used for the sandwich ELISA experiments
on dissociated mixed cell cultures prepared from four fetal
brains (16–19 gw). The assay was performed according to
manufacturer’s instructions. We used Origin to plot the standard
curve and analyze results from the ELISA experiment.
Statistics
All data were expressed asmean± standard error ofmean (SEM).
Mean, SEM, and p-values were calculated in Microsoft Excel. For
all experiments, data were averaged across the four brains (n =
4; 16–19 gw). Two-tailed Student’s t-test was used to compare
treated and control groups with statistical significance considered
p ≤ 0.05.
RESULTS
Cortical Progenitors and Neurons Express
NR1 at Mid-Gestation
Using the enriched dorsal RGCs cultures (see Materials and
Methods; Figure 1), we explored whether isolated RGCs express
NMDARs, particularly the obligatory subunit NR1, since KYNA
has a specific affinity toward the glycine site of the NR1 subunit
(Zhuravlev et al., 2007). Indeed, cultured human RGCs express
the NR1 subunit gene (Figures 2A,B) and protein (Figure 2C)
after 3 DIV of proliferation and 7DIV of differentiation in all fetal
brains studied (n = 4, 16–19 gw). Further, to determine which
progenitor subtypes express the NR1 subunit after 3 DIV we used
double immunolabeling with antibodies against NR1 and the
markers of cortical progenitors (Figure 2D). We demonstrated
that RGCs labeled with BLBP+, intermediate progenitors labeled
with Tbr2+, and a subpopulation of interneuron progenitors
labeled with Nkx2.1+, all express the NR1 subunit. After 7 DIV
of differentiation, the newly generated neurons labeled with βIII
tubulin, and also with Tbr1 or GABA, markers of glutamatergic
and cortical interneurons, respectively, express NR1 (Figure 2D).
In humans, GFAP is a marker of both RGCs progenitors and
differentiated astrocytes, and both cell types express NR1 subunit.
Notably, we observed two types of immunostaining: diffused
staining in progenitor cells, possibly due the presence of NR1 in
the Golgi network undergoing transport, and punctate staining
in neurons, which could reflect membrane localization of NR1 in
these cells.
Thus, based on these co-labeling experiments, we conclude
that at mid-gestation, both cortical progenitors, two neuronal
subtypes, glutamatergic and interneurons, and astroglia cells
express the NR1 subunit of NMDARs.
KYNA Affects Cell Survival and
Proliferation via Blockade of NMDARs
We further examined the effects of KYNA on proliferation and
survival of human RGCs. KYNA binds to the NR1 subunit of
NMDARs as well as to the nAChRs. To determine if the effect
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FIGURE 2 | Cell types that express NR1 subunit at mid-gestation. (A) Timeline showing that NR1 expression was analyzed on progenitors after 3 DIV in PM and
on mature cell types after 7 DIV in DM; n = 4. (B) qPCR and (C) Western blot showing NR1 gene and protein expression, respectively, mean ± SEM. (D)
Representative double immunolabeling images taken from 17 gw cultures for NR1 (green) with either progenitor, neuronal or astroglial markers (red). After 3 DIV in PM,
NR1 was expressed on BLBP+ RGCs, Tbr2+ intermediate progenitors, Nkx2.1+ interneuron progenitors, and on GFAP+ astroglia. After additional 7 DIV in DM, NR1
was expressed on neurons labeled with βIII tubulin, Tbr1, GABA, and on astrocytes labeled with GFAP. Nuclear stain: BB.
of KYNA on cell cycle and cell death was mediated through
NMDARs or nAChRs, we used receptor specific antagonists:
D-APV specific to NMDARs and TBC for nAChRs (Figure 3A).
Response curves were first plotted 48 h after RGC cultures
underwent treatments with eight different concentrations of
KYNA, D-APV, and TBC. The effect of KYNA on RGCs
proliferation and on cell survival was measured, and the effective
concentration at which 50% of the cell population was affected
(EC50) was determined in both assays. Considering that the
concentration 0.05 µM effectively induced 50% cell death
and concentration 0.01 µM effectively inhibited 50% of cell
proliferation (Figures 3B,C), we used the following treatment
concentrations for further experiments: 0.001, 0.005, and 0.01
µM of KYNA for 48 h. Furthermore, KYNA concentration-
response curves in both assays were similar to that of D-APV
while TBC curves were shifted to the right, suggesting that
in human RGC cultures KYNA exerts most of its effects on
cell survival and proliferation in a manner very similar to the
NMDAR-specific antagonist D-APV.
KYNA Alters RGC Specification
To examine the effects of KYNA on the specification of human
cortical progenitors, we followed the progeny of RGCs after
3 DIV of proliferation. Real-time PCR revealed that after
KYNA treatment expression of genes specific to progenitor
subtypes is decreased in a concentration-dependent manner,
while expression of the astroglial gene, Gfap is increased with
the highest KYNA concentration of 0.01 µM (p < 0.05;
Figure 4A).
Protein expression, examined in whole cell lysates using
Western blotting, revealed that treatment with KYNA
significantly reduced expression levels of proteins specific
for cortical progenitors. While only the highest concentration
of KYNA (0.01 µM) had significant (p < 0.05) effects on RGC
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FIGURE 3 | Concentration-response curve for in vitro KYNA treatment. (A) Timeline of the experiment. (B) The live/dead assay: live (green) and dead cells (red)
for control (DMSO) and drug treatments. (C) Ki67+ proliferating cells (red); nuclear stain BB (blue); n = 4; p < 0.05 between DMSO and each treatment. Mean ±
SEM; DMSO, Dimethyl sulfoxide; TBC, Tubocurarine chloride; D-APV, D-amino phosphonovalerate.
protein BLBP and intermediate progenitor protein Tbr2, all three
concentrations of KYNA reduced expression of protein Nkx2.1
present in subpopulation of cortical interneuron progenitors (p
< 0.05). In accordance with gene expression levels, astroglial
protein GFAP showed an increase after KYNA treatment in a
concentration-dependent manner (p< 0.05; Figures 4B,C).
Looking at the effects of KYNA on the cell types using
immunocytochemistry, we found that the percentage of BLBP+
RGCs and Tbr2+ intermediate progenitors from all cells
in the culture were significantly reduced with the two
highest concentrations (0.005 and 0.01 µM), while all three
concentrations of KYNA significantly decreased the percentage
of Nkx2.1+ interneuron progenitors (p < 0.05). These results
were in line with those observed from the qPCR and Western
blotting experiments. Similar to data on gene and protein
expression, we found a significant increase in the GFAP+
astroglial population in KYNA treated cultures (p < 0.05;
Figures 4D,E).
These results indicate that KYNA significantly altered the
specification of the cortical radial glia progenitor cells by
reducing the number of progenitor subtypes (Tbr2, Nkx2.1)
while increasing the number of GFAP+ astroglial cells, the
first type of glia to appear once neurogenesis is completed in
vivo. This alteration in the progenitor specification timeline
is likely to alter the downstream process of neurogenesis and
gliogenesis.
KYNA Modifies the Process of Neuronal
Differentiation
Since KYNA negatively affected RGCs and altered their
specification process, we hypothesized that the process of
progenitor cells differentiating into cortical neurons is also
affected. In order to test our hypothesis, we added differentiation
medium (DM) to our progenitor cell cultures for 7 DIV and then
assessed their differentiation into either neurons or astrocytes.
Gene expression analysis using real time PCR showed that
KYNA decreased expression of neuronal genes Neurogenin
1/2, Tbr1, and Gad65 in a concentration-dependent manner,
but increased expression of astrocytic gene Gfap (p < 0.05;
Figure 5A). This finding was further supported by the decrease
in neuronal proteins βIII tubulin and Tbr1, but an increase
in astrocytic protein GFAP after KYNA treatment (p < 0.05;
Figures 5B,C). Although we demonstrated decrease in mRNA
levels in progenitors (Figure 4A) as well as in neurons and
astrocytes (Figure 5A), we need to take into account that a
pharmacological treatment affects the viability of the cells which
limits the interpretation of these results.
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FIGURE 4 | Blocking NMDAR affects cell fate determination in vitro. (A) KYNA treatment decreased progenitors but increased astroglia specific gene
expression in a concentration-dependent manner, (B) Western blot from 17 gw KYNA treated cell lysates, and (C) the densitometric analysis showed a decrease in
progenitor, but increase in astroglia protein expression in a concentration-dependent manner. (D) Representative images at 17 gw for immunolabeling with specific
progenitor and astroglia markers (red), and nuclear stain: BB (blue). (E) The immunolabeling quantification showed a decrease in percentage of progenitor subtypes,
but an increase in astroglia population (n = 4; * represents p < 0.05). Scale bar 50 µm.
To analyze the effect on specific cell-types, we performed
immunocytochemistry using antibodies specific to neuronal
proteins. We observed a significant decrease in the number
of cells labeled with neuronal markers (β-III-tubulin, Tbr1,
GABA, Calretinin) and this decrease was KYNA concentration-
dependent. Moreover, the decrease of GABAergic neurons was
50% and glutamatergic (Tbr1) neurons 17% comparing to
controls, suggesting a greater effect of KYNA on interneuron
vs. glutamatergic neurogenesis. Once again, we found an
increase in the number of GFAP+ astrocytes, indicating a
drive toward astrocyte formation (p < 0.05; Figures 5D,E). We
have not, however, observed any differences in oligodendrocyte
progenitors (O4+ cells) or mature oligodendrocytes (MBP+
cells) in our KYNA treated cultures (not shown).
Combined results obtained with a battery of methods
demonstrated that KYNA influenced the RGC specification
and differentiation process by increasing the astroglial cell
population at the expense of neuronal cells. Developmentally,
this shift in gliogenesis occurring before neurogenesis
could be detrimental to cortical circuitry formation and
function.
KYNA Treatment Increases the Population
of Reactive Astrocytes
It has been previously reported that KYNA triggers activation of
astrocytes and generates an inflammatory response that involves
secretion of pro-inflammatory cytokines (Guillemin et al., 2001;
Meyer et al., 2011). To test this possibility, we used mixed cell
cultures that contain both neurons and glia cells, and have a
higher number of astroglial cells (GFAP+) than the enriched
RGC cultures (Figure 6A; Mo et al., 2007). We treated mixed
cortical cultures with the same concentrations of KYNA as used
for the enriched RGC cultures, i.e., 0.001, 0.005, and 0.01 µM,
for 24 and 48 h and performed cell survival and proliferation
assays as previously described. The highest level of KYNA used,
0.01 µM, induced 30% more cell death compared to control
(Figure 6B; p < 0.05), and decreased cell proliferation by 21.4%
compared to control (Figure 6C; p < 0.01). We immunolabeled
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FIGURE 5 | Differential effect of KYNA treatment on neural cell types. (A) q-PCR showed that KYNA treatment decreased neuronal specific (Neurogenin, Tbr1,
Gad65), but increased astrocytic gene (Gfap) expression (B)Western blot from 17 gw KYNA treated cell lysates, and (C) Densitometric analysis showed a decrease in
expression for neuron specific proteins, but an increase for astrocytic protein (D) Immunostaining at 17 gw for neuron and astrocytic markers (red); nuclei labeled with
BB (blue). (E) Quantification of the immunolabeled cell types showed a decrease in neuronal cell populations, but an increase in the astrocyte cell population (n = 4;
* represents p < 0.05).
KYNA treated mixed cell cultures with an antibody to S100β, a
cytoplasmic marker for reactive astrocytes.
Quantification of the number of S100β+ cells immediately
after the 48 h KYNA treatment revealed that treatment with
KYNA induced a significant increase in S100β+ cells, from 0.5%
in control conditions to 40% when treated with 0.01 µM KYNA
(p < 0.001; Figure 6D). These S100β+ astrocytes were large cells
with multiple processes. Reactive astrocytes are a well-known
source of pro-inflammatory cytokines, one of which is IL-6, a
primary cytokine released in almost all inflammatory responses
(Guillemin et al., 2001; Islam et al., 2009). Since we observed a
strong gliosis reaction in our KYNA-treated mixed cell cultures,
we determined the level of secreted cytokine IL-6. We measured
concentration of secreted IL-6 in the medium at 24 and 48 h
after KYNA treatment, and observed significant increase in levels
of IL-6 in KYNA treated cultures, at both time points. These
changes were concentration-dependent, as shown in Figure 6E.
After 24 h, the concentration of IL-6 was increased in cells treated
with all three concentrations of KYNA, however, significance was
achieved only for concentrations 0.005 µM, and 0.01 µMKYNA
(p < 0.05), as compared to DMSO (control). After 48 h, the IL-6
concentration was increased in all treated cell cultures regardless
of KYNA concentration (p < 0.01). The possible reason why
we did not observe differences in IL-6 levels between different
concentrations of KYNA could be due to the saturation of essay
sensitivity in presence of high concentrations of IL6.
DISCUSSION
In the present study, we explored the effects of KYNA on
human cerebral cortical development in cell cultures derived
from mid-gestational human tissue. Previous studies in rodents
(Malatesta et al., 2000; Miyata et al., 2001; Noctor et al., 2001,
2004), and humans (Clowry et al., 2010; Hansen et al., 2010;
Betizeau et al., 2013; Malik et al., 2013; Radonjic´ et al., 2014)
have shown significant species-specific differences demonstrating
critical need for studies of cortical development in human
cultures. Three major findings from this study demonstrate
that KYNA, acting as an antagonist of NMDARs, significantly
alters proliferation, specification and differentiation of cortical
cells generated from enriched RGC cultures. First, after KYNA
treatment, RGC proliferation and survival decreased resulting
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FIGURE 6 | KYNA treatment activated astrocytes and induced IL-6 secretion in mixed cell cultures. (A) Mixed cell cultures (18 gw) labeled with RGCs,
astrocytes and neuronal markers. (B) The live/dead and (C) proliferation assays showed that KYNA treatment decreased cell viability and proliferation in a
concentration-dependent manner. (D) Immunolabeling for S100b+ (red). The percentage of S100β+ reactive astrocytes increased after 48 h KYNA treatment. (E)
KYNA treated cultures at 24 and 48 h time points exhibited increase in IL-6 secretion as compared to DMSO control. Nuclear stain: BB; n = 4; * represents p < 0.05.
Mean ± SEM.
in a reduced number of cortical progenitors (Nkx2.1+ and
Tbr2+ cells), neurons (βIII tubulin+, Tbr1+, CalR+), and
interneurons (GABA+). Second, KYNA treatment effectively
pushed the specification of RGCs toward the astroglial lineage,
as evidenced by the increase in number of GFAP+ cells after
3 DIV of proliferation. Not only did the number of GFAP+
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astrocytes increase, but in addition astrocytes were activated
as demonstrated by morphological changes and S100β labeling.
Third, KYNA exposure triggered an inflammatory response as
evidenced by increased levels of the pro-inflammatory cytokine
IL-6. In sum, these results indicate that altered levels of KYNA
during human gestation, may have profound effects on cortical
development, and through activation of astrocytes, initiate an
inflammatory response resulting in a positive feedback loop.
KYNA Disrupts Neurogenesis and Reduces
the Pool of Cortical Progenitors In vitro
KYNA is a product of the kynurenine pathway, the main
metabolic route of tryptophan degradation, and is responsible
for a broad spectrum of effects, including the endogenous
regulation of neuronal excitability and the initiation of immune
tolerance. KYNA is the only known endogenous antagonist of
the NMDAR in vivo, and binds strongly to the NR1 subunit
(Kessler et al., 1989; Wang et al., 2006). However, KYNA also
inhibits α7nAChRs (Hilmas et al., 2001; Alkondon et al., 2004),
and both NMDAR and nAChRs are expressed early during
human development (4–5 gw; Kostovic´ et al., 1989; Hellström-
Lindahl et al., 1998; Suzuki et al., 2006). Therefore, it was
necessary to distinguish which receptor mediates KYNA effects
on the early developing brain. In this study, we showed that in
RGCs, KYNA acts similar to NMDAR-specific antagonist D-APV,
corroborating previous studies that showed KYNA’s inability to
block nAChR-dependent electrical activity in cultured adult rat
cortical and hippocampal cells (Hilmas et al., 2001; Mok et al.,
2009; Dobelis et al., 2012).
During embryonic development in rodents and humans,
NMDARs are important for proliferation of neural stem cells,
their differentiation into neurons and glia, and proper migration
of the differentiated cell types to their correct position in the
six-layered cerebral cortex (Manent et al., 2005; Suzuki et al.,
2006; Toriumi et al., 2012). In vivo blockade of NMDARs during
rat cortical development induces apoptosis of neuronal and glial
cells leading to severe neurodegeneration and ultimately death
of the animal (Ikonomidou et al., 1999). In vitro, we observed
that antagonizing NMDARs with KYNA increases cell death of
cortical progenitors and decreases RGC proliferation, showing
the importance of NMDARs for both survival and proliferation of
RGCs in the human cerebral cortex during the second trimester
of gestation.
KYNA-Induced Changes in Cell Fate
Determination
An important issue is whether KYNA has differential effects
on generation of principal neurons and interneurons in the
developing cortex. To study this question, we used various
transcription factors to label distinct neuronal populations in
vitro. Transcription factor Nkx2.1 is a marker of a subpopulation
of cortical interneuron progenitors (Rakic and Zecevic, 2003;
Zecevic et al., 2005; Jakovcevski et al., 2011), and Tbr2 is a
marker of glutamatergic progenitors in the developing human
cerebral cortex (Bayatti et al., 2008; Yu and Zecevic, 2011; Malik
et al., 2013; Pollen et al., 2015). This study confirmed our
previous results that human RGCs have a capacity to generate
both Nkx2.1+ and Tbr2+ cells in vitro (Yu and Zecevic, 2011)
and indicated further commitment of RGCs to both interneuron
and glutamatergic lineages. For example, after allowing time
for differentiation, a percentage of fetal cortical RGCs start
expressing GABA a major interneuron transmitter. On similar
grounds, after differentiation cortical RGCs were shown to
express Tbr1, a transcription factor downstream of Tbr2,
indicating commitment to the glutamatergic lineage (Englund
et al., 2005). Most notably, we have shown that a KYNA-induced
decrease in progenitors (Nkx2.1 and Tbr2) resulted further in a
decrease of GABAergic interneurons and Tbr1+ glutamatergic
neurons. Notably, the decrease of GABAergic neurons was more
pronounced than that of glutamatergic neurons. These data
suggest that a KYNA-induced alteration in the cortical progenitor
pool disrupts neurogenesis and may affect the proportional
balance of cortical cell types and subsequent formation of cortical
circuitry.
KYNA Elicits Pro-Inflammatory Response
Mounting evidence suggests a link between maternal immune
activation and neuropsychiatric illness (Gilmore and Jarskog,
1997; Buka et al., 2001). The KYNA-mediated NMDAR blockade
favored astrocyte generation, as had been shown previously in
human fetal astrocyte cultures (Guillemin et al., 2001), and in
addition, induced the activation of resting astrocytes in both
RGC cultures and mixed cell cultures. The morphology of
S100β+ cells changed, and their number increased, implying a
pro-inflammatory response. Interestingly, astrocytic hypertrophy
has been reported in the prefrontal cortex of patients with
bipolar disorder (Rajkowska et al., 2001), indicating that reactive
astrocytic changes can be a major component of neuropsychiatric
illness.
We also showed increased levels of secreted IL-6, a pro-
inflammatory cytokine, in our human culture medium following
KYNA treatment. This is in agreement with reports in mice that
KYNA causes the release of inflammatory cytokines, especially
IL-6 and IFN-γ (Islam et al., 2009). Moreover, in vitro, both IFN-
γ and IL-6 activate human fetal astrocytes to synthesize large
amounts of KYNA (Guillemin et al., 2001; Islam et al., 2009;
Meyer et al., 2011; Schwieler et al., 2015). Activation of cytokines
is directly relevant to schizophrenia as studies in human subjects
found elevated levels of IL-6 in the cerebrospinal fluid of Sch
patients in comparison to their age and sex-matched healthy
counterparts (Garver et al., 2003; Schwieler et al., 2015). With
respect to the potential developmental pathways involved, KYNA
has been shown to elicit a pro-inflammatory response that can
activate the JAK-STAT pathway in mice (Schwarcz et al., 2001;
Erhardt et al., 2012; Holtze et al., 2012). This would result
in cytokine-receptor interactions and could interfere with the
normal specification of cortical progenitors at mid-gestation.
Consequences of Elevated KYNA Levels
during Fetal Neurodevelopment
Metabolites of the kynurenine pathway have important roles in
the CNS, and recent data imply a role in brain development
as well (reviewed in Notarangelo and Pocivavsek, 2016).
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Physiological levels of KYNA are higher in the developing brain
compared to the immediate post-natal period and adulthood
(Beal et al., 1992; Walker et al., 1999; Ceresoli-Borroni and
Schwarcz, 2000). It has been suggested that KYNA might protect
the fetal brain from over-excitation via NMDARs (Badawy,
2014). At the same time, glutamate via activation of NMDARs has
an important trophic role in neurodevelopment. Various insults
during pregnancy can lead to direct physiological changes in
the fetal environment, thereby influencing the normal course
of prenatal brain development. For example, the anesthetic
ketamine and drugs of abuse such as PCP and ethanol antagonize
normal function of fetal cortical NMDARs (Anis et al., 1983;
Krystal et al., 1994; Lahti et al., 1995; Lieberman et al., 2012;
Xiang et al., 2015). These disruptions may have long-lasting
consequences for subsequent brain and behavioral development
and might lead to structural and functional brain abnormalities
in adult life (Iaccarino et al., 2013).
Even though it is well established that KYNA acts as
an antagonist of NMDAR and nAChR, the consequences of
pathological levels of KYNA in the developing brain have not
been fully explored. Our in vitro study shows that KYNA, by
antagonizing NMDARs, negatively influences the proliferation of
human RGCs and pushes RGC specification toward astrocytes,
vs. neurons. In addition, higher KYNA concentrations, while
negatively impacting both interneurons and principle neurons,
results in larger deficits in GABA+ interneurons compared to
a Tbr1+ subpopulation of projection neurons. The preferential
vulnerability of interneurons might be clinically relevant
since impaired function of cortical interneurons is reported
in neurodevelopmental disorders including Sch and autism
spectrum disorder (Akbarian et al., 1995; DeFelipe, 1999; Knable,
1999; Gleeson and Walsh, 2000; Lewis and Levitt, 2002; Levitt,
2003; Baraban and Tallent, 2004; Lewis et al., 2005). In our
study, human cortical progenitors were isolated at mid-gestation
(16–19 gw), an important period of active neurogenesis when
upper cortical layers are formed (Hill and Walsh, 2005). As these
layers are crucial for formation of cortico-cortical connections
and subsequently for emergence of higher brain functions,
interference with NMDARs that are expressed on all cortical cell
types (Bagasrawala et al., 2016) at this developmentally sensitive
period may lead to a widespread effect on formation of the
cortical circuitry. Together, these changes can have a negative
impact on cortical functional maturation during adolescence,
a stage when cognitive executive functions, such as planning,
rational thinking, attention, and emotion-related impulsivity
control develop, and a time point at which Sch symptoms often
first manifest (Uhlhaas, 2011). The effects of KYNA on human
cortical progenitors in vitro, reported in this study, are still
preliminary. Further studies are, therefore, needed to determine
if KYNA exerts its effect on RGCs by a selective or inductive
action mechanism.
Certainly, in vitro systems have limitations, and further
studies are needed to discern the complexity of developmental
disruption caused by NMDAR antagonism. However, the
in vitro system studied here serves as an innovative tool for
understanding the possible effects of endogenous molecules,
when present at pathologic levels, on human fetal cortical
development. This method enables us to identify the
specific cellular targets of KYNA but also to determine
possible cell signaling molecules involved in human cortical
development.
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